Union Minister Sadanand Gowda on Wednesday said the Department of Pharmaceuticals has approved the lifting of ban on the export of anti-malarial drug hydroxychloroquine API as well as its formulations.
“Manufacturers except SEZ/EOU Units have to supply 20% production in the domestic market. DGFT has been asked to issue a formal notification in this regard,” he said on Twitter.
Department of Pharmaceuticals has approved the lifting of ban on Export of Hydroxychloroquine API as well as formulations. Manufacturers except SEZ/EOU Units have to supply 20% production in the domestic market. DGFT has been asked to issue formal notification in this regard.
— Sadananda Gowda (@DVSadanandGowda) June 10, 2020
India has ramped up output of the drug, which has been hailed by US President Donald Trump as a “game-changer” in the fight against coronavirus, even as its pharmaceutical industry struggles to make other key medicines in a lockdown.
Drug companies have seen demand for hydroxychloroquine soar since March when Trump’s remarks sparked a run on the medication and caused a global shortage – despite health agencies warning over its safety in the treatment of Covid-19.
India accounts for 70 per cent of the global production of hydroxychloroquine, which is also used to treat lupus and rheumatoid arthritis.
Despite the challenges, Indian companies have managed to export the medicine to 97 countries during the pandemic, the health ministry said.
Brazil, Germany and a number of South Asian and African nations are reported to have been among those to ask India for major supplies of the medicine as they deal with the contagion.